Ciraparantag

Ciraparantag
Clinical data
Synonyms PER977
N1,N1′-[Piperazine-1,4-diylbis(propane-1,3-diyl)]bis-L-argininamide
Routes of
administration		 Intravenous
ATC code
  • None
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Onset of action 10 min
Duration of action 24 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C22H48N12O2
Molar mass 512.71 g·mol−1
3D model (JSmol)

Ciraparantag (INN/USAN, or aripazine) is a drug under investigation as an antidote for a number of anticoagulant (anti-blood clotting) drugs, including factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), dabigatran, low molecular weight heparins and unfractionated heparin.[1][2]

Mechanism of action

According to in vitro studies, the substance binds directly to anticoagulants via hydrogen bonds from or to various parts of the molecule:[1]

Hydrogen bonds Rivaroxaban Apixaban Edoxaban Dabigatran Heparins
Guanidine part Green tick Green tick Green tick Green tick
α-Amino group Green tick Green tick Green tick Green tick
Amide nitrogen Green tick Green tick Green tick
Amide oxygen Green tick Green tick

Chemical properties

Ciraparantag consists of two L-arginine units connected with a piperazine containing linker chain.[1]

See also

Other anticoagulant antidotes

References

  1. 1 2 3 Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel Herbst 2015 (in German)
  2. ↑ Ansell, J. E. (2015). "Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants". Journal of Thrombosis and Thrombolysis. 41: 248–52. doi:10.1007/s11239-015-1288-1. PMID 26449414.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.